Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation. A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S et al. Acta Haematol. 2014 Mar 22;132(2):211-219. [Epub ahead of print].

Pathways for blood and bowel cancer patients in the last year of life: describing inpatient care patterns using routine national data.
Kane E et al. BMJ Support Palliat Care. 2014 Mar 1;4(1):116. doi: 10.1136/bmjspcare-2014-000653.34.

Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
Franken MG et al. Value Health. 2014 Mar;17(2):245-53. doi: 10.1016/j.jval.2013.12.009.

Physical activity in relation to risk of hematologic cancers: a systematic review and meta-analysis.
Jochem C et al. Cancer Epidemiol Biomarkers Prev. 2014 Mar 14. [Epub ahead of print].

A population-based cohort study of late mortality in adult autologous HSCT recipients in Australia.
Ashton LJ et al. Biol Blood Marrow Transplant. 2014 Mar 13. pii: S1083-8791(14)00155-4. doi: 10.1016/j.bbmt.2014.03.006. [Epub ahead of print].

Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies.
Shen K et al. PLoS One. 2014 Mar 13;9(3):e91461. doi: 10.1371/journal.pone.0091461. eCollection 2014.

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
Proskorovsky I et al. Health Qual Life Outcomes. 2014 Mar 11;12(1):35. doi: 10.1186/1477-7525-12-35.

Venous Thromboembolism and Cancer Risk among Elderly Adults in the U.S.
Marks MA et al. Cancer Epidemiol Biomarkers Prev. 2014 Mar 8. [Epub ahead of print].

Pomalidomide: A Review of Its Use in Patients with Recurrent Multiple Myeloma.
Scott LJ et al. Drugs. 2014 Mar 4. [Epub ahead of print].

Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups.
Libby E et al. Leuk Lymphoma. 2014 Mar 4. [Epub ahead of print].

The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
Brioli A et al. Br J Haematol. 2014 Mar 2. doi: 10.1111/bjh.12805. [Epub ahead of print].

Leukemia, lymphoma and multiple myeloma mortality (1950-1999) and incidence (1969-1999) in the Eldorado uranium workers cohort.
Zablotska LB et al. Environ Res. 2014 Apr;130:43-50. doi: 10.1016/j.envres.2014.01.002. Epub 2014 Feb 28.

Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: A systematic review and meta-analysis.
Lopuch S et al. Hematology. 2014 Feb 28. [Epub ahead of print].

Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.
Brioli A et al. Expert Rev Anticancer Ther. 2014 Mar 3. [Epub ahead of print].

New Approaches to Management of Multiple Myeloma.
Genadieva-Stavric S et al. Curr Treat Options Oncol. 2014 Mar 1. [Epub ahead of print].

Bortezomib and lenalidomide as front-line therapy for multiple myeloma.
RosiƱol L et al. Leuk Lymphoma. 2014 Mar 20. [Epub ahead of print].

Multiple myeloma in Nigeria: an insight to the clinical, laboratory features, and outcomes.
Madu AJ et al. Niger J Clin Pract. 2014 Mar-Apr;17(2):212-7. doi: 10.4103/1119-3077.127561.

Alcohol drinking and multiple myeloma risk–a systematic review and meta-analysis of the dose-risk relationship.
Rota M et al. Eur J Cancer Prev. 2014 Mar;23(2):113-21. doi: 10.1097/CEJ.0000000000000001